If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMortgage Advice Bureau Regulatory News (MAB1)

Share Price Information for Mortgage Advice Bureau (MAB1)

Share Price is delayed by 15 minutes
Get Live Data
526.00    0.00 (0.00%)
Bid:
508.00
Ask:
534.00
Spread: 26.00 (5.118%)
Market Cap: £303.05m
MAB1 Live PriceLast checked at - London Stock Exchange

Intraday Mortgage Advice Bureau Share Chart

Trading Update

23 Jan 2025 07:00

RNS Number : 3653U
Mortgage Advice Bureau (Hldgs) PLC
23 January 2025
 

 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for this announcement is Emilie McCarthy, CFO.

 

23 January 2025

 

Mortgage Advice Bureau (Holdings) plc

("MAB" or the "Group")

 

Trading Update

Board Changes

 

Mortgage Advice Bureau (Holdings) plc (AIM: MAB1) today issues a trading update for the year ended 31 December 2024, ahead of publishing its final results on Tuesday, 18 March 2025.

 

Year ended 31 December 2024

Group revenue for year ended 31 December 2024 increased by 11% to c.£266m (2023: £239.5m), which is significantly higher than the estimated 4% growth (1) in UK gross lending for the same period. The Board expects to report growth in Adjusted PBT for the year of c. 31% to c. £30.5m (2023: £23.2m) which is c. 4% ahead of consensus (2), excluding the £1.5m positive impact of the capitalisation of Midas platform internal development costs in 2024.

MAB's number of mainstream advisers grew modestly in the second half, increasing to 1,941 at the year-end (2023: 1918). However, lower than expected growth in adviser numbers was more than offset by a significant rise in productivity. The average revenue per mainstream adviser grew c.12% to c. £138k (2023: £123.5k). Improving operational efficiency is a key area of focus across the Group, supported by technology enhancements and lead-generation initiatives.

Current trading and outlook

Clear signs of pent-up demand were evidenced by the increase in mortgage applications in Q4 2024 (+15% compared to Q4 2023) and we expect this positive momentum to be maintained. UK Finance forecasts (1) gross new lending to rise 11% in 2025 in £235bn, which we believe is a realistic estimate.

In addition, the delivery of new technology enhancements and lead generation initiatives are expected to drive further growth this year, with many AR firms expecting to see adviser numbers increase, alongside a continued focus on increasing profitability through rising productivity.

 

 

 

 

 

Board changes

MAB is pleased to announce that subject to regulatory approval, Paul Gill, Chief Risk Officer, will be joining the Board as an Executive Director.

 

David Preece, Non-Executive Director, has decided not to seek re-election at the next AGM. The Board would like to thank David for his enormous contribution to MAB, as an Executive Director from 2004 to 2019, and as a Non-Executive Director since 2019.

 

The Board intends to add two additional Independent Non-Executive Directors.

 

Capital Markets Day

As previously announced, MAB will host a Capital Markets Day in London from 14:00 to 17:00 on 5 February 2025. The event will be held at the London Stock Exchange and will be webcast live for those who cannot attend in person.

 

The event will include updates on strategy, growth plans, technology and lead generation initiatives from our Executive Directors and members of our senior management team. We will also discuss medium-term targets and a proposed new capital allocation policy, further details of which will be pre-released via RNS on 4 February 2025.

 

If you would like to register your interest in the event, please contact Camarco: mab@camarco.co.uk.

 

 

Peter Brodnicki, CEO of MAB, commented:

"Despite two challenging years in terms of UK mortgage volumes, I am very pleased with how MAB has performed. We have increased strategic spend over this period and are starting to see the benefits of this come through in the positive momentum we're building.

 

We expect purchase transactions to steadily increase over the next year, whilst several years of strong refinancing transactions will provide additional opportunities for growth.

 

We are seeing increased optimism among many of our ARs, and as a result, expect to see organic growth in adviser numbers start to return in a more meaningful way. Following a slower period in terms of new AR recruitment, we plan to onboard more firms this year while continuing to explore value-accretive acquisitions.

 

The step up in productivity in 2024 has been very pleasing, so our focus for this year is on maintaining that momentum, supported by development in technology and AI, and our continued focus on lead generation."

 

(1) - UK Finance Mortgage Market Forecasts published in December 2024

(2) - Consensus estimate 2024 adjusted PBT - £29.2m. 

 

 

Enquiries:

 

Mortgage Advice Bureau (Holdings) plc

Via Camarco

 

Peter Brodnicki, Chief Executive Officer

Ben Thompson, Deputy Chief Executive Officer

Emilie McCarthy, Chief Financial Officer

 

Nominated Adviser and Joint Broker

Keefe, Bruyette & Woods, a Stifel Company

Erik Anderson / Nick Harland / Francis North / Harry Billen

 

 

+44 (0)20 7710 7600

Joint Broker

Peel Hunt LLP

Andrew Buchanan / Oliver Jackson

 

 

 

+44 (0) 20 7418 8900

Financial PR

Camarco

Tom Huddart / Louise Dolan / Letaba Rimell

 

 

mab@camarco.co.uk

+44 (0) 203 757 4980

Investor Relations

Investor.relations@mab.org.uk

 

About Mortgage Advice Bureau:

 

MAB is one of the UK's leading consumer intermediary brands and specialist networks for mortgage advisers. 

 

Through its partner firms known as Appointed Representatives ("ARs"), MAB has approximately 2,000 advisers providing expert advice to customers on a range of mortgage, specialist lending, protection, and general insurance products. MAB supports its AR firms with proprietary technology and services, including adviser recruitment and lead generation, learning and development, compliance auditing and supervision, and digital marketing and website solutions.

 

For more information, visit www.mortgageadvicebureau.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFFILDIFFIE
Date   Source Headline
22nd May 20247:00 amRNSAGM Statement
17th May 20243:26 pmRNSNotification of Major Holdings
14th May 20244:37 pmRNSDirectors' Shareholdings and PDMR notification
10th May 20247:00 amRNSNotification of Major Holdings
1st May 20247:00 amRNSNotification of Major Holdings
30th Apr 20242:21 pmRNSDirectors' Shareholdings and PDMR notification
25th Apr 20244:40 pmRNSNotice of Results and AGM
23rd Apr 20244:27 pmRNSGrant of Options and Total Voting Rights
23rd Apr 20247:00 amRNSBoard Changes
17th Apr 20244:57 pmRNSPDMR dealing
15th Apr 20246:09 pmRNSDirector/PDMR Shareholding
28th Mar 20244:01 pmRNSDirectors' Shareholdings and PDMR notification
19th Mar 20247:00 amRNSFinal Results for the year ended 31 December 2023
15th Mar 20247:00 amRNSDirectors' Shareholdings and PDMR notification
8th Mar 202411:41 amRNSNotification of Major Holdings
29th Feb 20243:21 pmRNSDirectors' Shareholdings and PDMR notification
23rd Feb 20243:25 pmRNSNotification of Major Holdings
19th Feb 20246:17 pmRNSNotification of Major Holdings
19th Feb 20246:15 pmRNSNotification of Major Holdings
14th Feb 20244:09 pmRNSDirectors' Shareholdings and PDMR notification
9th Feb 20247:00 amRNSNotification of Major Holdings
6th Feb 20243:15 pmRNSNotification of Major Holdings
31st Jan 20243:38 pmRNSDirectors' Shareholdings and PDMR notification
26th Jan 20247:00 amRNSNotification of Major Holdings
25th Jan 20247:00 amRNSTrading Update
15th Jan 20243:15 pmRNSDirectors' Shareholdings and PDMR notification
15th Jan 20247:00 amRNSBoard Change
12th Jan 20241:43 pmRNSBlock listing Interim Review
29th Dec 202311:03 amRNSDirectors' Shareholdings and PDMR notification
15th Dec 202310:26 amRNSDirectors' Shareholdings and PDMR notification
30th Nov 20235:57 pmRNSDirectors' Shareholdings and PDMR notification
21st Nov 202311:49 amRNSNotification of Major Holdings
14th Nov 20234:29 pmRNSDirectors' Shareholdings and PDMR notification
3rd Nov 20233:43 pmRNSDirector/PDMR Shareholding
31st Oct 20234:00 pmRNSDirectors' Shareholdings and PDMR notification
16th Oct 20235:07 pmRNSDirectors' Shareholdings and PDMR notification
12th Oct 202311:10 amRNSNotification of Major Interest in Shares
10th Oct 20231:32 pmRNSNotification of Major Interests in Shares
9th Oct 20235:55 pmRNSNotification of Major Interests in Shares
28th Sep 202312:11 pmRNSNotification of Major Holdings
26th Sep 20237:00 amRNSInterim Results
18th Sep 20232:40 pmRNSDirectors' Shareholdings and PDMR notification
31st Aug 20234:43 pmRNSDirectors' Shareholdings and PDMR notification
14th Aug 20233:24 pmRNSDirector/PDMR Shareholding
10th Aug 20237:00 amRNSStandard form for notification of major holdings
1st Aug 202311:23 amRNSDirector/PDMR Shareholding
26th Jul 20237:00 amRNSTrading Update
21st Jul 20232:59 pmRNSNotification of major holdings
18th Jul 20235:34 pmRNSDirectors' Shareholdings and PDMR notification
17th Jul 202312:43 pmRNSDirectors' Shareholdings and PDMR notification

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.